Results 101 to 110 of about 110,621 (200)

Modular Synthesis of Targeted Molecular Imaging Agents for MRI, PET, and PET-MRI of Cancer

, 2019
Molecular imaging is a field widely used in the diagnosis and treatment of cancer. We offer here a modular method for the synthesis of targeted molecular imaging agents (TMIAs), which will improve the accuracy of current molecular imaging methods, as ...
Jones, Kelsea
core  

Positron emission tomography molecular imaging for pathological visualization in multiple system atrophy

Neurobiology of Disease
Multiple system atrophy (MSA) is a complex, heterogeneous neurodegenerative disorder characterized by a multifaceted pathogenesis. Its key pathological hallmark is the abnormal aggregation of α-synuclein, which triggers neuroinflammation, disrupts both ...
La Dong, Rui Zhou, Jinyun Zhou, Ke Liu, Chentao Jin, Jing Wang, Chenxi Xue, Mei Tian, Hong Zhang, Yan Zhong   +9 more
doaj   +1 more source

Iron oxide nanoparticles and derivatives for biomedical imaging and application in cancer diagnosis and siRNA therapy

, 2011
This paper was presented at the 3rd Micro and Nano Flows Conference (MNF2011), which was held at the Makedonia Palace Hotel, Thessaloniki in Greece.
Yigit, MV, Medarova, Z, 3rd Micro and Nano Flows Conference (MNF2011)   +2 more
core  

Construction of in-situ self-assembled agent for NIR/PET dual-modal imaging and photodynamic therapy for hepatocellular cancer

Journal of Nanobiotechnology
Hepatocellular cancer (HCC) remained a life-threatening carcinoma. Agents for HCC imaging and therapy were expected to possess different intratumoral retention time.
Xinmiao Lu, Yucheng Fu, Yunyun Zhu, Chuang Xi, Quanyong Luo, Hua Pang   +5 more
doaj   +1 more source

Perspective on This Article from Fluorinated COX-2 Inhibitors as Agents in PET Imaging of Inflammation and Cancer

, 2011
Perspective on This Article from Fluorinated COX-2 Inhibitors as Agents in PET Imaging of Inflammation and ...
Jeffery Reese (15096996), Kebreab Ghebreselasie (1275462), Lawrence J. Marnett (1264209), Mohammed N. Tantawy (1275459), Md. Jashim Uddin (587776), Philip J. Kingsley (1267866), Mohammad Sib Ansari (15096993), Imran Huda (1314906), Brenda C. Crews (1275456)   +8 more
core   +1 more source

PET imaging of PARP expression using [18F]olaparib

, 2018
PARP inhibitors are increasingly being studied as cancer drugs, as single agents or as a part of combination therapies. Imaging of PARP using a radiolabeled inhibitor has been proposed for patient selection, outcome prediction, dose optimization ...
Kersemans, V, Hueting, Rebekka, Torres, Julia Baguña, Wilson, T, Mosley, Michael, Allen, Phillip, Smart, Sean, Cornelissen, B, Verhoog, S, Xavier, Mary-Ann, Verhoog, Stefan, Allen, Phillip D, Gouverneur, V, Hueting, R, Mosley, M, Hopkins, SL, Smart, S, Torres, JB, Cornelissen, Bart, Knight, J, Wallington, S, Wallington, Sheena, Kersemans, Veerle, Allen, P, Wilson, Thomas C, Cornelissen, Bart; id_orcid, Hopkins, Samantha L, Xavier, M-A, Knight, James, Gouverneur, Véronique, Wilson, Thomas, Hopkins, Samantha   +31 more
core   +1 more source

Progress in studying iron-based magnetic resonance contrast agents

上海师范大学学报. 自然科学版
In recent years, iron-based magnetic resonance contrast agents have received widespread attention in the medical imaging field due to their excellent magnetic properties and good biocompatibility.
GUO Zepei, YANG Shiping
doaj   +1 more source

A comparison of PET imaging agents for the assessment of therapy efficacy in a rodent model of glioma.

American journal of nuclear medicine and molecular imaging, 2013
The aim of the current study was to assess the ability of PET imaging agents to detect early response to therapy in an orthotopic experimental rodent model of glioma. Clinically, MRI and [(18)F]FDG PET are routinely used but their ability to assess early therapeutic response can be limited.
Moonshi, Shehzahdi S., Bejot, Romain, Atcha, Zeenat, Vijayaragavan, Vimalan, Bhakoo, Kishore K., Goggi, Julian L.   +5 more
openaire   +3 more sources

Effect of MR Contrast Agents on Quantitative Accuracy of PET in Combined Whole-Body PET/MR Imaging

, 2011
Combined whole-body PET/MR systems are being tested in clinical practice today. Integrated imaging protocols entail the use of MR contrast agents (MRCA) that could bias PET attenuation correction.
Beyer, T., Werner, M., Kupferschläger, J., Bezrukov, I., Pichler, B., Schwenzer, N., Schmidt, H., Lois, C.   +7 more
core  

Development of [F-18]-Labeled Amyloid Imaging Agents for PET

, 2007
The applicant proposes to design and synthesize a series of fluorine-18-labeled radiopharmaceuticals to be used as amyloid imaging agents for positron emission tomography (PET).
Mathis, C. A.
core   +1 more source